Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Rapid Dose and McMaster University's COVID-19 vaccine study receives NSERC R&D grant

Stockhouse Editorial
2 Comments| December 23, 2021

{{labelSign}}  Favorites
{{errorMessage}}

Rapid Dose Therapeutics Corp. (RDT) (CSE.DOSE, OTCMKTS: RDTCF, Forum) – a Canadian biotechnology company revolutionizing drug delivery through innovation – has announced that the ongoing development of an orally delivered vaccine candidate for COVID-19 has received the final installment of the Collaborative Research and Development grant, with a value of $120,000, from the Natural Sciences and Engineering Research Council of Canada (NSERC).

Mark Upsdell, CEO of Rapid Dose Therapeutics, commented:

“We appreciate the ongoing support received from the Canadian government through NSERC as we continue to drive this important research forward. Global experts have called for a needle-free method of delivering vaccines for COVID-19 and many other diseases, and this research is paramount to supporting the commercialization of such an innovation.”

Full story here.


About Rapid Dose Therapeutics

Rapid Dose Therapeutics Corp. is a publicly-traded Canadian Life Sciences company providing innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers Quick, Convenient, Precise and Discreet™ choices to consumers. RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry — including nutraceutical, pharmaceutical and cannabis industries. RDT’s service-based annuity contracts drive recurring revenue and facilitate rapid expansion into emerging markets across multiple consumer segments. RDT is committed to continually create innovative solutions for humans, animals, and plants.


New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.

For more of the latest info on Cannabis, check out the Cannabis Trending News hub. Or, for lively sector discussion, visit Stockhouse’s new Cannabis Bullboards page.


FULL DISCLOSURE: Rapid Dose Therapeutics Corp. is a client of Stockhouse Publishing.


{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today